En rollover-undersøgelse for deltagere, der tidligere er tilmeldt en Genentech- og/eller F. Hoffman-La Roche-sponsoreret undersøgelse (UmbrellaMAX)
3. november 2026 opdateret af: Hoffmann-La Roche
Et åbent, multicenter udvidelsesstudie i patienter, der tidligere er tilmeldt en Genentech og/eller F. Hoffmann-La Roche Ltd sponsoreret undersøgelse
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP[s]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
Studieoversigt
Status
Status
Rekruttering
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
Tilmelding
200
Fase
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
Studiekontakt
- Navn: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Undersøgelse Kontakt Backup
- Navn: Reference Study ID Number: BX44273 https://forpatients.roche.com/ No attachments to email below.
- Telefonnummer: 888-662-6728 (U.S. Only)
- E-mail: global-roche-genentech-trials@gene.com
Studiesteder
-
-
-
Charleroi, Belgien, 6060
- Afsluttet
- GHdC Site Les Viviers
-
Kortrijk, Belgien, 8500
- Aktiv, ikke rekrutterende
- AZ Groeninge
-
Leuven, Belgien, 3000
- Aktiv, ikke rekrutterende
- UZ Leuven Gasthuisberg
-
Leuven, Belgien, 3000
- Afsluttet
- UZ Leuven Gasthuisberg
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1Z5
- Rekruttering
- Princess Margaret Cancer Center
-
-
-
-
-
San José, Costa Rica, 10103
- Aktiv, ikke rekrutterende
- Clinica CIMCA
-
San José, Costa Rica, 10108
- Aktiv, ikke rekrutterende
- ICIMED Instituto de Investigación en Ciencias Médicas
-
-
-
-
-
Leicester, Det Forenede Kongerige, LE1 5WW
- Rekruttering
- Leicester Royal Infirmary
-
Surrey, Det Forenede Kongerige, SM2 5PT
- Afsluttet
- Royal Marsden Hospital - Surrey
-
-
-
-
-
Bordeaux, Frankrig, 33076
- Rekruttering
- Institut Bergonie
-
Caen, Frankrig, 14076
- Rekruttering
- Centre Francois Baclesse
-
Dijon, Frankrig, 21000
- Rekruttering
- Institut de Cancérologie de Bourgogne
-
Lyon, Frankrig, 69373
- Rekruttering
- Centre Leon Berard
-
Marseille, Frankrig, 13005
- Rekruttering
- Hopital de la Timone
-
Montpellier, Frankrig, 34298
- Rekruttering
- Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque
-
Nantes, Frankrig, 44093
- Rekruttering
- CHU de Nantes - Hotel Dieu
-
Nîmes, Frankrig, 30029
- Afsluttet
- Institut de cancerologie du Gard
-
Paris, Frankrig, 75005
- Rekruttering
- Institut Curie
-
Paris, Frankrig, 75970
- Rekruttering
- Hopital Tenon
-
Saint-Herblain, Frankrig, 44805
- Rekruttering
- ICO - Site René Gauducheau
-
Toulouse, Frankrig, 31059
- Rekruttering
- Institut Claudius Regaud
-
Vandœuvre-lès-Nancy, Frankrig, 54511
- Rekruttering
- Hopitaux de Brabois - Gastro-Entereologie
-
Villejuif, Frankrig, 94800
- Rekruttering
- Gustave Roussy
-
-
Bouches-du-Rhône
-
Marseille, Bouches-du-Rhône, Frankrig, 13005
- Rekruttering
- AP-HM- Hôpital de La Timone
-
-
-
-
-
Asvestochóri, Grækenland, 570 10
- Rekruttering
- General Hospital "G.Papanikolaou"
-
Cholargós, Grækenland, 155 62
- Rekruttering
- Metropolitan General Hospital
-
-
-
-
-
Chiba, Japan, 277-8577
- Rekruttering
- National Cancer Center Hospital East
-
Chuo-ku, Fukuoka-shi, Japan, 810-8563
- Rekruttering
- National Hospital Organization Kyushu Medical Center
-
Fukuoka, Japan, 812-8582
- Rekruttering
- Kyushu University Hospital
-
Kanagawa, Japan, 232-0024
- Aktiv, ikke rekrutterende
- Yokohama City University Medical Center
-
Kanagawa, Japan, 241-8515
- Afsluttet
- Kanagawa Cancer Center
-
Kanagawa, Japan, 213-8587
- Rekruttering
- Toranomon Branch Hospital
-
Kashiwa-shi, Japan, 277-8577
- Rekruttering
- National Cancer Center Hospital East
-
Matsuyama, Japan, 791-0280
- Rekruttering
- National Hospital Organization Shikoku Cancer Center
-
Numakunai, Japan, 028-3695
- Rekruttering
- Iwate Medical University Hospital
-
Saitama, Japan, 362-0806
- Rekruttering
- Saitama Cancer Center
-
Sakaishi, Japan, 591-8555
- Rekruttering
- NHO Kinki-Chuo Chest Medical Center
-
-
-
-
-
Beijing, Kina, 100142
- Rekruttering
- Beijing Cancer Hospital
-
Changchun, Kina, 130021
- Rekruttering
- the First Hospital of Jilin University
-
Chengdu, Kina, 610041
- Rekruttering
- West China Hospital of Sichuan University
-
Guangzhou, Kina, 510515
- Rekruttering
- Nanfang Hospital, Southern Medical University
-
Guangzhou, Kina, 510000
- Rekruttering
- Cancer Center of Guangzhou Medical University
-
Hangzhou, Kina, 310022
- Rekruttering
- Zhejiang Cancer Hospital
-
Hangzhou, Kina, 310014
- Rekruttering
- Zhejiang People's Hospital
-
Hangzhou, Kina, 310016
- Rekruttering
- Sir Run Run Shaw Hospital Zhejiang University
-
Harbin, Kina, 150081
- Rekruttering
- Harbin Medical University Cancer Hospital
-
Hefei, Kina, 230601
- Rekruttering
- The Second Affiliated Hospital of Anhui Medical University
-
Meizhou, Kina, 514031
- Rekruttering
- Meizhou People's Hospital
-
Nanchang, Kina, 330052
- Rekruttering
- The 1st Affiliated Hospital of Nanchang Unversity
-
Nanjing, Kina, 210029
- Rekruttering
- Jiangsu Province Hospital of Chinese Medicine
-
Shanghai, Kina, 200030
- Rekruttering
- Shanghai Chest Hospital
-
Shanghai, Kina, 200120
- Rekruttering
- Fudan University Shanghai Cancer Center
-
Shanghai, Kina, 201104
- Rekruttering
- Shanghai Geriatric Medical Center
-
Tianjin, Kina, 300060
- Rekruttering
- Tianjin Cancer Hospital
-
Xi'an, Kina, 710061
- Rekruttering
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University
-
Xi'an, Kina, 710126
- Rekruttering
- Xi'an International Medical Center Hospital
-
Xiamen, Kina, 361003
- Rekruttering
- The First Affiliated Hospital of Xiamen University
-
Xinxiang, Kina
- Rekruttering
- The First Affiliated Hospital of Xinxiang Medical University
-
Zhengzhou, Kina, 450008
- Rekruttering
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, Kina, 430048
- Rekruttering
- Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
-
-
Shaanxi
-
XI 'an City, Shaanxi Province, Shaanxi, Kina, 710061
- Rekruttering
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Rekruttering
- Fudan University Shanghai Cancer Center
-
-
-
-
-
Durango, Mexico, 34000
- Aktiv, ikke rekrutterende
- Consultorio de Especialidad en Urologia Privado
-
-
Sinaloa
-
Culiacán, Sinaloa, Mexico
- Aktiv, ikke rekrutterende
- Centro Medico Culiacan SA de CV
-
-
Yucatán
-
Mérida, Yucatán, Mexico, 97070
- Afsluttet
- Medical Care & Research
-
-
-
-
-
Gda?sk, Polen, 80-214
- Rekruttering
- Uniwersyteckie Centrum Kliniczne
-
Koszalin, Polen, 75-581
- Rekruttering
- Szpital Wojewódzki im. Miko?aja Kopernika
-
Warsaw, Polen, 02-781
- Rekruttering
- Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie
-
-
-
-
Moscow Oblast
-
Moscow, Moscow Oblast, Rusland, 117997
- Aktiv, ikke rekrutterende
- Russian Scientific Center of Roentgenoradiology
-
Moscow, Moscow Oblast, Rusland, 125248
- Rekruttering
- P.A. Herzen Oncological Inst.
-
Moscow, Moscow Oblast, Rusland, 121205
- Rekruttering
- Moscow City Oncology Hospital #62
-
Moskva, Moscow Oblast, Rusland, 119991
- Rekruttering
- I.M.Sechenov First Moscow State Medical University (1st MSMU)
-
-
-
-
-
Goyang-si, Sydkorea, 10408
- Rekruttering
- National Cancer Center
-
Gyeonggi-do, Sydkorea, 13496
- Rekruttering
- CHA Bundang Medical Center
-
Seongnam-si, Sydkorea, 463-707
- Afsluttet
- Seoul National University Bundang Hospital
-
Seoul, Sydkorea, 06351
- Rekruttering
- Samsung Medical Center
-
Seoul, Sydkorea, 05505
- Aktiv, ikke rekrutterende
- Asan Medical Center
-
-
-
-
-
Taichung, Taiwan, 407
- Rekruttering
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 70457
- Rekruttering
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 110
- Rekruttering
- National Taiwan University Hospital
-
Taoyuan, Taiwan, 333
- Aktiv, ikke rekrutterende
- Chang Gung Memorial Hospital - Linkou
-
-
-
-
-
Bangkok, Thailand, 10700
- Rekruttering
- Siriraj Hospital
-
Bangkok, Thailand, 10330
- Aktiv, ikke rekrutterende
- Chulalongkorn Hospital
-
Chiang Mai, Thailand, 50200
- Aktiv, ikke rekrutterende
- Maharaj Nakorn Chiangmai Hospital
-
-
-
-
-
Kyiv, Ukraine, 02000
- Rekruttering
- Arensia Exploratory Medicine - Ukraine
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Eligible for continuing Roche IMP-based therapy at the time of roll-over from the parent study, as per the parent study protocol OR
- Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent
- First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study
- Continue to benefit from the Roche IMP-based therapy or comparator at the time of roll-over from the parent study as assessed by the investigator
- Ability to comply with the extension study protocol, per Investigator's judgement
Exclusion Criteria:
- Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study
- Study treatment or comparator agent is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant
- Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this extension study
- Permanent discontinuation of all study treatment(s) or comparator agent(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable)
- Ongoing SAE(s) that has not resolved to baseline level or Grade ≤1 from the parent study or during the time between the last treatment in the parent study and the first dose of study treatment in this extension study. Potential participants with an ongoing SAE that has not resolved to baseline level or Grade 1 may be enrolled at the investigator's discretion, provided the event is deemed clinically stable and the investigator documents that the potential clinical benefit outweighs the risk to the potential participant.
- Concurrent participation in any therapeutic clinical trial (other than the parent study)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
2
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Roche IMP(s) Monotherapy
Participants will continue to receive Roche IMP(s) monotherapy as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawal of study consent, unacceptable toxicity, pregnancy, participants non-compliance, if local access becomes available or study termination by the Sponsor, whichever occurs first. |
Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
Atezolizumab will be administered as a monotherapy and in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants' discontinuation from the parent study.
Andre navne:
Bevacizumab will be administered as a monotherapy or in combination with atezolizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
Entrectinib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
Inavolisib will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
Divarasib will be administered as a monotherapy or in combination with atezolizumab or bevacizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
Giredestrant will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
|
|
Eksperimentel: Roche Combined Agents
Participants will continue to receive Roche IMP(s) in combination with other agent(s) as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawal of study consent, unacceptable toxicity, pregnancy, participants non-compliance, if local access becomes available or study termination by the Sponsor, whichever occurs first. |
Atezolizumab will be administered as a monotherapy and in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants' discontinuation from the parent study.
Andre navne:
Bevacizumab will be administered as a monotherapy or in combination with atezolizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
Inavolisib will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
Divarasib will be administered as a monotherapy or in combination with atezolizumab or bevacizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
Tiragolumab and Atezolizumab in fixed dose combination administered intravenously (IV) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
Giredestrant will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antal deltagere med fortsat adgang til Roche IMP(er)-baseret terapi og/eller sammenligningsagent(er)
Tidsramme: Op til cirka 10 år
|
Op til cirka 10 år
|
|
Antal og sværhedsgrad af deltagere med udvalgte uønskede hændelser vurderet i henhold til National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0
Tidsramme: Op til cirka 10 år
|
Op til cirka 10 år
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
Studiestart
1. juni 2023
Primær færdiggørelse (Anslået)
Primær færdiggørelse
1. marts 2033
Studieafslutning (Anslået)
Studieafslutning
1. marts 2033
Datoer for studieregistrering
Først indsendt
Først indsendt
1. maj 2023
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
16. maj 2023
Først opslået (Faktiske)
Først opslået
17. maj 2023
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
6. november 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
3. november 2026
Sidst verificeret
Sidst verificeret
1. november 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- BX44273
- 2022-003414-36 (EudraCT nummer)
- 2023 (U.S. NIH-bevilling/kontrakt)
- 2023-504263-16-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .